Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
22 participants
INTERVENTIONAL
2010-03-31
2013-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of PF-04360365 On ABETA In Patients With Alzheimer's Disease And Healthy Volunteers
NCT01005862
Modulation of Abeta Levels by GSK933776 in Alzheimer's Disease Patient
NCT01424436
Improving Beta-2 Adrenergic Signaling in Alzheimer's Disease
NCT02500784
Long-term Safety and Tolerability of AFFITOPE AD01
NCT00711139
CNS and Plasma Amyloid-Beta Kinetics in Alzheimer's Disease
NCT02021682
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Acitretin
oral, 30 mg per day, day 1-28
Acitretin
30mg per day from Day 1 to Day 28
Placebo
oral, day 1-28
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Acitretin
30mg per day from Day 1 to Day 28
Placebo
Placebo
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Mini-Mental State Examination (MMSE): 27-14 points
* Geriatric Depression Scale ≤ 14
Exclusion Criteria
* known history of brain injuries
* Insufficient German language skills
* actual treatment with other potential disease modifying drugs of AD
* multimorbidity or significant organ (esp. liver or renal) dysfunction
* evidence of Non-AD neurodegenerative disorder (e.g. Parkinson)
* contraindication to acitretin such as osteoporosis, hypoalbuminaemia
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alzheimer Forschungsinitiative e.V. (AFI)
UNKNOWN
K. Lieb
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
K. Lieb
Herr Univ.-Prof. Dr. med. Andreas Fellgiebel
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andreas Fellgiebel, PD Dr.
Role: PRINCIPAL_INVESTIGATOR
Department of psychiatry and psychotherapy, University medical center of the Johannes Gutenberg-University Mainz, Germany
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of psychiatry and psychotherapy, University medical center of the Johannes Gutenberg-University Mainz
Mainz, Rhineland-Palatinate, Germany
Universität Rostock
Rostock, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2009-011881-27
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
ADAM
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.